Million Women Study

https://neurodegenerationresearch.eu/survey/million-women-study/

Title of the cohort

Million Women Study

Acronym for cohort

MWS

Name of Principal Investigator

Title Professor
First name Valerie
Last name Beral

Address of institution where award is held

Institution Cancer Epidemiology Unit, University of Oxford

Street Address Richard Doll Building, Roosevelt Drive

City Oxford OX3 7LF

Country

United Kingdom

Website

www.millionwomenstudy.org

Contact email

lynden.guiver@ceu.ox.ac.uk

Funding source

Cancer Research UK Medical Research Council Health and Safety Executive

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Motor neurone diseases
- Parkinson's disease

When studies on the above condition(s) are expected to become possible

2011 - 2015

2a. Stated aim of the cohort

To study hormonal, reproductive and other factors affecting women's health from middle age onwards

2b. Features distinguishing this cohort from other population cohorts

Large size Complete follow-up through linkage to NHS records for deaths, cancer registrations and hospital admissions Detailed demographic and lifestyle information Blood samples available for several thousand women

3a. i) Number of publications that involve use of cohort to date

58

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)3b. Publication list/link to where data or publications are accessible (if available)

Study website

3c. Information (i.e. research findings) expected to be gained from the population cohort 4a. Study criteria: age range of participants at recruitment

Age in years from: 50-64

To ('until death' if applicable): until death **4b. Study criteria: inclusion criteria**

45. Study Silicina. Molasion Silicina

All women invited for NHS breast screening appointment during recruitment phase were invited to take part; those who attended screening and completed the study questionnaire were included

4c. Study criteria: exclusion criteria

see above

5. Size of the cohort (i.e. number of participants enrolled)

More than 15,000

6a. Measures used to characterise participants

Very wide range: details on website

Age at recruitment and date of birth

Region

Townsend deprivation index

Smoking, alcohol

Medication

Height, weight, waist, hip; derived BMI

Physical activity

Diet

Reproductive factors including detailed use of hormone replacment therapy

Medical history Family history

Genetic factors for subset of cohort

6b. Additional measures for participants with a clinical disorder

No

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

Breast cancer incidence and mortality were the primary endpoints for the study, but other cancer and non-cancer endpoints have always been included

7. Study design

Prospective cohort

8. Cases matched by

- Other health assessment (specify) / N/A
- not matched

9a. Does the study include a specialised subset of control participants

No

9b. If yes, description of specialised subset of control participants 10a. i) Data collection start date

01-01-1996

10a. ii) Data collection end date10a iii) Data collection for this study is

- Data collection ongoing
- Data analysis ongoing
- Closed to new patients

10b. Plans to continue the cohort study beyond the current projected end date

Yes – intend to apply for funding

11. Data collected

Through links to medical records

12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

Yes/No % available

Data summarised in database yes

Database is web-based Database on spreadsheet Database is on paper

Other (specify)

Language used:

13b. Format and availability of data held as individual records

Yes/No % available

Data held as individual records

Yes

Data is web-based

Data held on computer based records Yes

Data held on cards

Other (specify)

Language used:

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource
- Access through collaboration with PI only

15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

Living donors:blood

16b. ii) Form available tissues/samples/DNA are supplied in

Secondary samples: derivatives of primary samples

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

No